Decreased NURR1 gene expression in patients with Parkinson's disease.
Identifieur interne : 000136 ( PubMed/Corpus ); précédent : 000135; suivant : 000137Decreased NURR1 gene expression in patients with Parkinson's disease.
Auteurs : Weidong Le ; Tianhong Pan ; Maosheng Huang ; Pingyi Xu ; Wenjie Xie ; Wen Zhu ; Xiong Zhang ; Hao Deng ; Joseph JankovicSource :
- Journal of the neurological sciences [ 0022-510X ] ; 2008.
English descriptors
- KwdEn :
- Age Factors, Antipsychotic Agents (pharmacology), Antipsychotic Agents (therapeutic use), DNA-Binding Proteins (genetics), DNA-Binding Proteins (metabolism), Female, Gene Expression Regulation (drug effects), Gene Expression Regulation (physiology), Humans, Male, Nuclear Receptor Subfamily 4, Group A, Member 2, Odds Ratio, Parkinson Disease (drug therapy), Parkinson Disease (genetics), Sex Factors, Transcription Factors (genetics), Transcription Factors (metabolism).
- MESH :
- chemical , genetics : DNA-Binding Proteins, Transcription Factors.
- chemical , metabolism : DNA-Binding Proteins, Transcription Factors.
- chemical , pharmacology : Antipsychotic Agents.
- chemical , therapeutic use : Antipsychotic Agents.
- drug effects : Gene Expression Regulation.
- drug therapy : Parkinson Disease.
- genetics : Parkinson Disease.
- physiology : Gene Expression Regulation.
- Age Factors, Female, Humans, Male, Nuclear Receptor Subfamily 4, Group A, Member 2, Odds Ratio, Sex Factors.
Abstract
NURR1 is a transcription factor essential for the development, survival, and functional maintenance of midbrain dopaminergic (DAergic) neurons and NURR1 is a potential susceptibility gene for Parkinson's disease (PD). To determine whether NURR1 gene expression is altered in patients with PD, we measured its expression in human peripheral blood lymphocytes (PBL) in 278 patients with PD, 166 healthy controls (HC), and 256 neurological disease controls (NDC) by quantitative real-time PCR. NURR1 gene expression was significantly decreased in patients with PD (particularly those with family history of PD) as compared with HC (p<0.01) and also as compared with NDC (p<0.05). There was no significant difference in NURR1 gene expression among PD patients with or without anti-PD medications. When adjusted for gender, age, and ethnicity, lower levels of NURR1 gene expression were associated with significantly increased risk for PD in women, in patients 60 years old or older, and in patients of Caucasian origin. The observed reduction in PBL NURR1 gene expression indicates possible systemic involvement in PD, and the finding may help identify individuals with PD and other disorders associated with impaired central DAergic system.
DOI: 10.1016/j.jns.2008.06.007
PubMed: 18684475
Links to Exploration step
pubmed:18684475Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Decreased NURR1 gene expression in patients with Parkinson's disease.</title><author><name sortKey="Le, Weidong" sort="Le, Weidong" uniqKey="Le W" first="Weidong" last="Le">Weidong Le</name><affiliation><nlm:affiliation>Parkinson Disease Research Laboratory, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Pan, Tianhong" sort="Pan, Tianhong" uniqKey="Pan T" first="Tianhong" last="Pan">Tianhong Pan</name></author><author><name sortKey="Huang, Maosheng" sort="Huang, Maosheng" uniqKey="Huang M" first="Maosheng" last="Huang">Maosheng Huang</name></author><author><name sortKey="Xu, Pingyi" sort="Xu, Pingyi" uniqKey="Xu P" first="Pingyi" last="Xu">Pingyi Xu</name></author><author><name sortKey="Xie, Wenjie" sort="Xie, Wenjie" uniqKey="Xie W" first="Wenjie" last="Xie">Wenjie Xie</name></author><author><name sortKey="Zhu, Wen" sort="Zhu, Wen" uniqKey="Zhu W" first="Wen" last="Zhu">Wen Zhu</name></author><author><name sortKey="Zhang, Xiong" sort="Zhang, Xiong" uniqKey="Zhang X" first="Xiong" last="Zhang">Xiong Zhang</name></author><author><name sortKey="Deng, Hao" sort="Deng, Hao" uniqKey="Deng H" first="Hao" last="Deng">Hao Deng</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="doi">10.1016/j.jns.2008.06.007</idno><idno type="RBID">pubmed:18684475</idno><idno type="pmid">18684475</idno><idno type="wicri:Area/PubMed/Corpus">000136</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Decreased NURR1 gene expression in patients with Parkinson's disease.</title><author><name sortKey="Le, Weidong" sort="Le, Weidong" uniqKey="Le W" first="Weidong" last="Le">Weidong Le</name><affiliation><nlm:affiliation>Parkinson Disease Research Laboratory, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Pan, Tianhong" sort="Pan, Tianhong" uniqKey="Pan T" first="Tianhong" last="Pan">Tianhong Pan</name></author><author><name sortKey="Huang, Maosheng" sort="Huang, Maosheng" uniqKey="Huang M" first="Maosheng" last="Huang">Maosheng Huang</name></author><author><name sortKey="Xu, Pingyi" sort="Xu, Pingyi" uniqKey="Xu P" first="Pingyi" last="Xu">Pingyi Xu</name></author><author><name sortKey="Xie, Wenjie" sort="Xie, Wenjie" uniqKey="Xie W" first="Wenjie" last="Xie">Wenjie Xie</name></author><author><name sortKey="Zhu, Wen" sort="Zhu, Wen" uniqKey="Zhu W" first="Wen" last="Zhu">Wen Zhu</name></author><author><name sortKey="Zhang, Xiong" sort="Zhang, Xiong" uniqKey="Zhang X" first="Xiong" last="Zhang">Xiong Zhang</name></author><author><name sortKey="Deng, Hao" sort="Deng, Hao" uniqKey="Deng H" first="Hao" last="Deng">Hao Deng</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></author></analytic><series><title level="j">Journal of the neurological sciences</title><idno type="ISSN">0022-510X</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term><term>Antipsychotic Agents (pharmacology)</term><term>Antipsychotic Agents (therapeutic use)</term><term>DNA-Binding Proteins (genetics)</term><term>DNA-Binding Proteins (metabolism)</term><term>Female</term><term>Gene Expression Regulation (drug effects)</term><term>Gene Expression Regulation (physiology)</term><term>Humans</term><term>Male</term><term>Nuclear Receptor Subfamily 4, Group A, Member 2</term><term>Odds Ratio</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (genetics)</term><term>Sex Factors</term><term>Transcription Factors (genetics)</term><term>Transcription Factors (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>DNA-Binding Proteins</term><term>Transcription Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>DNA-Binding Proteins</term><term>Transcription Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Gene Expression Regulation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Gene Expression Regulation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Female</term><term>Humans</term><term>Male</term><term>Nuclear Receptor Subfamily 4, Group A, Member 2</term><term>Odds Ratio</term><term>Sex Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">NURR1 is a transcription factor essential for the development, survival, and functional maintenance of midbrain dopaminergic (DAergic) neurons and NURR1 is a potential susceptibility gene for Parkinson's disease (PD). To determine whether NURR1 gene expression is altered in patients with PD, we measured its expression in human peripheral blood lymphocytes (PBL) in 278 patients with PD, 166 healthy controls (HC), and 256 neurological disease controls (NDC) by quantitative real-time PCR. NURR1 gene expression was significantly decreased in patients with PD (particularly those with family history of PD) as compared with HC (p<0.01) and also as compared with NDC (p<0.05). There was no significant difference in NURR1 gene expression among PD patients with or without anti-PD medications. When adjusted for gender, age, and ethnicity, lower levels of NURR1 gene expression were associated with significantly increased risk for PD in women, in patients 60 years old or older, and in patients of Caucasian origin. The observed reduction in PBL NURR1 gene expression indicates possible systemic involvement in PD, and the finding may help identify individuals with PD and other disorders associated with impaired central DAergic system.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18684475</PMID><DateCreated><Year>2008</Year><Month>09</Month><Day>01</Day></DateCreated><DateCompleted><Year>2009</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2014</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0022-510X</ISSN><JournalIssue CitedMedium="Print"><Volume>273</Volume><Issue>1-2</Issue><PubDate><Year>2008</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of the neurological sciences</Title><ISOAbbreviation>J. Neurol. Sci.</ISOAbbreviation></Journal><ArticleTitle>Decreased NURR1 gene expression in patients with Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>29-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jns.2008.06.007</ELocationID><Abstract><AbstractText>NURR1 is a transcription factor essential for the development, survival, and functional maintenance of midbrain dopaminergic (DAergic) neurons and NURR1 is a potential susceptibility gene for Parkinson's disease (PD). To determine whether NURR1 gene expression is altered in patients with PD, we measured its expression in human peripheral blood lymphocytes (PBL) in 278 patients with PD, 166 healthy controls (HC), and 256 neurological disease controls (NDC) by quantitative real-time PCR. NURR1 gene expression was significantly decreased in patients with PD (particularly those with family history of PD) as compared with HC (p<0.01) and also as compared with NDC (p<0.05). There was no significant difference in NURR1 gene expression among PD patients with or without anti-PD medications. When adjusted for gender, age, and ethnicity, lower levels of NURR1 gene expression were associated with significantly increased risk for PD in women, in patients 60 years old or older, and in patients of Caucasian origin. The observed reduction in PBL NURR1 gene expression indicates possible systemic involvement in PD, and the finding may help identify individuals with PD and other disorders associated with impaired central DAergic system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Weidong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Parkinson Disease Research Laboratory, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Tianhong</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Maosheng</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Pingyi</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Wen</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiong</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Hao</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NINSD-043567</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NINSD-40370</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS040370</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS040370-04</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS043567</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS043567-04</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neurol Sci</MedlineTA><NlmUniqueID>0375403</NlmUniqueID><ISSNLinking>0022-510X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C539882">NR4A2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057126">Nuclear Receptor Subfamily 4, Group A, Member 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1999 Nov;73(5):2218-21</RefSource><PMID Version="1">10537083</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76</RefSource><PMID Version="1">18344392</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm (Vienna). 2001;108(7):803-7</RefSource><PMID Version="1">11515746</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2002 Mar 26;58(6):881-4</RefSource><PMID Version="1">11914402</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Comp Neurol. 2002 Aug 26;450(3):203-14</RefSource><PMID Version="1">12209851</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Genet. 2003 Jan;33(1):85-9</RefSource><PMID Version="1">12496759</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Mol Med. 2003 Mar;9(3):126-32</RefSource><PMID Version="1">12657434</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2003 May;60(5):722-5</RefSource><PMID Version="1">12756136</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Biotechnol. 2003 Jun;21(6):660-6</RefSource><PMID Version="1">12754519</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 2003 Dec;1010:675-8</RefSource><PMID Version="1">15033810</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2004 May;19(5):544-8</RefSource><PMID Version="1">15133818</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Endocrinol. 1992 Dec;6(12):2129-35</RefSource><PMID Version="1">1491694</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Endocrinol. 1994 Nov;8(11):1583-91</RefSource><PMID Version="1">7877627</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1996 Mar;46(3):791-5</RefSource><PMID Version="1">8618685</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1997 Apr 11;276(5310):248-50</RefSource><PMID Version="1">9092472</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1998 Feb;43(2):212-6</RefSource><PMID Version="1">9485062</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):4013-8</RefSource><PMID Version="1">9520484</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cell Neurosci. 1998 May;11(1-2):36-46</RefSource><PMID Version="1">9608532</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1999 Jan;56(1):33-9</RefSource><PMID Version="1">9923759</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1999 Sep;14(5):764-71</RefSource><PMID Version="1">10495037</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 1999 Oct;159(2):451-8</RefSource><PMID Version="1">10506516</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 2005 Jan;191(1):154-62</RefSource><PMID Version="1">15589522</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2005 Mar;62(3):351-2</RefSource><PMID Version="1">15767498</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2005 Nov;58(5):797-800</RefSource><PMID Version="1">16240356</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Prog Neurobiol. 2005 Sep-Oct;77(1-2):128-38</RefSource><PMID Version="1">16243425</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Comp Neurol. 2006 Jan 20;494(3):495-514</RefSource><PMID Version="1">16320253</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem Biophys Res Commun. 2006 Oct 13;349(1):162-6</RefSource><PMID Version="1">16930553</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):955-60</RefSource><PMID Version="1">17215369</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Jun 15;22(8):1133-7</RefSource><PMID Version="1">17443703</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2008 Jan;29(1):117-22</RefSource><PMID Version="1">17890097</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2008 Feb;131(Pt 2):389-96</RefSource><PMID Version="1">18222993</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 Feb 15;23(3):319-28</RefSource><PMID Version="1">18044702</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroreport. 1999 Sep 29;10(14):2907-10</RefSource><PMID Version="1">10549795</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D057126">Nuclear Receptor Subfamily 4, Group A, Member 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016017">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012737">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS70643</OtherID><OtherID Source="NLM">PMC2572302</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2008</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S0022-510X(08)00272-4</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2008.06.007</ArticleId><ArticleId IdType="pubmed">18684475</ArticleId><ArticleId IdType="pmc">PMC2572302</ArticleId><ArticleId IdType="mid">NIHMS70643</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000136 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000136 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:18684475
|texte= Decreased NURR1 gene expression in patients with Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:18684475" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |